Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Genetically Redesigned RSV Vaccine is Promising

J Infect Dis; ePub 2018 Mar 2; Buchholz, et al

A new live respiratory syncytial virus (RSV) vaccine holds promise against the infection, suggests a recent trial.

  • RSV seronegative children between 6 and 24 months of age were given either intranasal doses of a placebo of RSV cold-passage/stabilized 2 (RSVcps2) vaccine, a previously studied product that was altered with mutations to stabilize it against diattenuation.
  • 85% of the children were RSVcps2, 77% shed vaccine virus, and 59% developed at least a 4-fold increase in neutralizing antibody titers.
  • Placebo and vaccine recipients both experienced a 50% rate of respiratory tract, febrile illness, or both.

Citation:

Buchholz UJ, Cunningham CK, Muresan P, et al. Live respiratory syncytial virus (RSV) vaccine candidate containing stabilized temperature-sensitivity mutations is highly attenuated in RSV-seronegative infants and children. [Published online ahead of print March 2, 2018]. J Infect Dis. doi:10.1093/infdis/jiy066.